论文部分内容阅读
目的探讨左乙拉西坦(LEV)预防小儿热性惊厥(FS)复发的临床疗效。方法选取FS患儿72例,随机分为观察组和对照组各36例,对照组在常规治疗基础上给予丙戊酸长期口服治疗,观察组在常规治疗基础上给予LEV口服治疗。随访1.5年,每半年复查24h动态脑电图(AEEG)1次,记录2组患儿发热次数、FS复发次数、服药情况、药物不良反应及癫痫发生情况。结果 2组发热次数、癫痫发生率比较差异无统计学意义(P>0.05);观察组FS复发次数、FS复发率均低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论 LEV可有效预防小儿FS复发,不良反应小,但不能降低癫痫发生率。
Objective To investigate the clinical efficacy of levetiracetam (LEV) in preventing recurrence of pediatric febrile convulsion (FS). Methods Seventy-two children with FS were selected and randomly divided into observation group and control group with 36 cases each. The control group received long-term oral administration of valproate on the basis of conventional treatment. The observation group received oral administration of LEV on the basis of routine treatment. The patients were followed up for 1.5 years. The 24-hour dynamic electroencephalogram (AEEG) was reviewed every six months. The number of fever, FS recurrence, medication, adverse drug reaction and epilepsy were recorded in two groups. Results There was no significant difference in the frequency of fever and epilepsy between the two groups (P> 0.05). The frequency of FS recurrence and the recurrence rate of FS in the observation group were lower than those in the control group (P <0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, the difference was statistically significant (P <0.05). Conclusion LEV can effectively prevent the recurrence of children with small adverse reactions, but can not reduce the incidence of epilepsy.